1. Pharmacological studies have suggested that A3 receptors are present on central neurons. Recently this
adenosine receptor subtype has been identified in the rat and its presence in the central nervous system has been confirmed. 2. In this study we investigated the effects of acute intracerebroventricular (i.c.v.)
injections of N6-2-(4-aminophenyl)-ethyladenosine (
APNEA), a non-selective A3
adenosine receptor agonist, on arterial blood pressure (ABP) and heart rate (HR),
after treatment with
8-cyclopentyl-1,3-dipropylxanthine (
DPCPX), a selective antagonist of A1
adenosine receptors. 3. Anaesthetized rats, after
DPCPX (12 microg(-1) kg i.c.v.), were treated with
APNEA (0.4-4 microg kg(-1) i.c.v.) resulting in a transitory and dose-dependent decrease in arterial blood pressure without a change in heart rate.
APNEA also induced hypotensive responses after i.c.v. pretreatment with
aminophylline, at a dose of 20 microg kg(-1). In contrast, pretreatment 48 h before, with 4 microg kg(-1) i.c.v. of
pertussis toxin reduced the hypotensive effect induced by
APNEA. Administration of
APNEA at a higher dose (20 microg kg(-1) i.c.v.), after
DPCPX, induced a decrease in ABP of -66+/-5.4 mmHg and after 3 min a decrease in heart rate of -62+/-6.0 beats min(-1). Transection of the spinal cord abolished this significant fall in ABP, but not the decrease of HR. 4. These results suggest that a population of A3-receptors is present in the CNS, whose activation induces a decrease in blood pressure with no change of heart rate.